pMHC Antibody Discovery

All of the advantages of human monoclonal antibodies with the ability to target intracellular proteins enabled by our revolutionary technology platform, Retained DisplayTM (ReD).

ReD: Targeting Intracellular Proteins

Existing antibody-based therapies such as bispecific antibodies and CAR-T cells target proteins expressed on the cell surface. Myrio’s ReD platform is enabling antibody-based therapeutics to be developed against a much broader range of targets including those that are expressed intracellularly. While antibodies cannot access the interior of the cell, Myrio’s scFvs can target the same antigen presentation pathway used by T-cells, where fragments of intracellular proteins are presented on the cell surface. Myrio’s scFvs will dramatically increase the approaches to treating solid tumors, persistent viral infections, and certain autoimmune diseases.

Learn more about our technology
Innovation feature

COVID-19 ipsum dolor sit amet, consectetur afiplsicing elit

Learn more

Latest news

Myrio Therapeutics data published in Nature: unlocking new targets for antibody-based therapies

Myrio Therapeutics Pty Ltd (Myrio) today announced ground-breaking findings published in the Journal Nature. The study, titled Therapeutic Targeting…

Read More

CoVIC consortium publishes Global study on variant-resistant SARS-CoV-2 epitopes in Science

Myrio is proud to be part of the global CoVIC consortium, providing antibodies in the fight against COVID-19. The results of the consortiums work…

Read More

CAR TCR Summit: Myrio Tx shares transformational approach to targeted human antibody-based therapies

Myrio Therapeutics (Myrio Tx) is driving a new frontier of antibody-based therapies as the company’s Retained DisplayTM (ReD) antibody platform…

Read More

Our research and development partners